<table>
<thead>
<tr>
<th>Time</th>
<th>Talk Title</th>
</tr>
</thead>
</table>
| 08.40 – 08.55 | PRE-CLINICAL EFFICACY OF A NOVEL ANTI-INVASION NANOPARTICLE THERAPEUTIC IN COMBINATION WITH THE ANGIogenesis INHIBITOR BEvacizumAB FOR THE TREATMENT OF GlioblastoMA  
  1Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin 2,  
  2National Neurosurgical Department, Beaumont Hospital, Dublin 9,  
  3Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA,  
  4Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands,  
  5Department of Oncology and Cell Biology, Feinstein Institute for Medical Research at North Shore-LIJ, Manhasset, NY 11030, USA |
| 08.55 – 09.10 | THE DEVELOPMENT OF ADAM22 AS A PREDICTIVE MARKER FOR ENDOCRINE RESISTANT BREAST CANCER  
  Ben Doherty, J Bolger, D McCartan, C Byrne, D Vareslija, S Cocchiglia, A Hill, L Young  
  1Endocrine Oncology Lab, RCSI, Dublin, 2Surgery, Beaumont Hospital, Dublin |
| 09.10 – 09.25 | CDK7: A MARKER OF POOR PROGNOSIS AND TRACTABLE THERAPEUTIC TARGET IN TRIPLE-NEGATIVE BREAST CANCER  
  Bo Li, T Ni Chonghaile, Y Fan, R Kinger, AE O’Connor, DP O’Connor, WM Gallagher  
  1Cancer Biology and Therapeutics Laboratory, Conway Institute, University College Dublin, Dublin |
| 09.25 – 09.40 | SYNERGISTIC COMBINATION OF ONCOlytic ROEVIrus TYPE 3 (DEARING) AND RADIOTHERAPY IN MELANOma  
  Grainne McEntee, J Kyula, V Roulstone, C Gregory, M Coffey, KJ Harrington  
  1Targeted Therapy Team, Institute Cancer Research, London UK, 2Oncolytics Biotech. Inc, Calgary Canada |
| 09.40 – 09.55 | EphA2 is an essential driver of invasion and associated with the poor prognostic stem-like subgroup in early stage colorectal cancer.  
  Philip Dunne, D McArt, J Blayney, M Salto-Tellez, P Johnston, S Van Schaeybroeck  
  1Cancer Research Centre, Queens University Belfast, Belfast |
| 09.55 – 10.10 | ERYTHROPOIETIN RECEPTOR PROMOTES C-Myc Driven BREAST TUMOURIGENESIS  
  Kyle B Matchett, KK Chan, JA Coulter, MA Davidson, HF Yuen, CM McCrudden, P Maxwell, M El-Tanani, TR Lappin  
  1Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast,  
  2Institute of Molecular and Cell Biology, A*STAR, Singapore |
| 10.10 - 10.30 | Gold Sponsor Platform – Fannin  
  Introduction to Droplet Digital PCR: Advances in Cancer Research  
  Dr. Stephen Hague, European Droplet Digital PCR Applications Specialist for Biorad |
| 10.30 – 11.00 | TEA/COFFEE/POSTERS AND MEET THE SPONSORS |
| 11.00 – 12.30 | Plenary Session 1: Epigenetics and Disease States  
  Chairs: Dr Olga Piskareva (RCSI) and Dr Ken Nally (UCC) |
| 11.00 – 11.30 | “Epigenetic Drugs: Exploring New Pathways For Manipulating Tumour Cell Death”  
  Nick LaThangue (University of Oxford) |
| 11.30 – 12.00 | “Decoding Long non-coding RNAs in Cancer”  
  Jo Vandesompele, Ghent University, Belgium |
| 12.00 – 12.30 | “Polycomb Group Proteins in Cancer”  
  Adrian Bracken, Trinity College Dublin |
<p>| 12.30 – 12.50 | Gold Sponsor Presentation – Kevin Francis, Perkin Elmer |
| 12.50 – 14.00 | LUNCH |</p>
<table>
<thead>
<tr>
<th>TIME</th>
<th>TALK TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.00 – 15.30</td>
<td>Plenary Session 2: From Mouse To Man; Imaging And Cancer</td>
</tr>
<tr>
<td></td>
<td>Chairs: Prof. William Gallagher (UCD) and Dr Norma O’Donovan (DCU)</td>
</tr>
<tr>
<td>14.00 – 14.30</td>
<td>“Advances in Cancer Imaging Using Multispectral Optoacoustic Tomography”</td>
</tr>
<tr>
<td></td>
<td>Dr Christoph Hinzen (Technische Universität München, Germany)</td>
</tr>
<tr>
<td>14.30 – 15.00</td>
<td>“Improving the Predictive Value of Preclinical Models Through the Co-Clinical Trial Paradigm”</td>
</tr>
<tr>
<td></td>
<td>Andrew L. Kung M.D., Ph.D., Chief, Division of Pediatric Hematology/ Oncology/Stem Cell Transplantation, Robert and Ellen Kapito Professor of Pediatrics, Columbia University Medical Center, New York, USA</td>
</tr>
<tr>
<td>15.00 – 15.30</td>
<td>“Exploring New Frontiers in the Diagnostic and Therapeutic Applications of Microwaves”</td>
</tr>
<tr>
<td></td>
<td>Martin O’Halloran, National University of Ireland, Galway</td>
</tr>
<tr>
<td>15.30 – 16.00</td>
<td>TEA/COFFEE/POSTERS AND MEET THE SPONSORS</td>
</tr>
<tr>
<td>16.00 – 17.00</td>
<td>ORAL POSTER PRESENTATIONS</td>
</tr>
<tr>
<td></td>
<td>(Best Oral Poster Presentation will receive the Prof. John Fitzpatrick Award)</td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr Robert O’Connor (ICS) and Dr Emer Bourke (NUIG)</td>
</tr>
<tr>
<td>16.00 – 16.06</td>
<td>INFLUENCE OF BACTERIA ON CHEMOTHERAPEUTIC DRUGS</td>
</tr>
<tr>
<td></td>
<td>Panos Lehouritis¹, J Cummins¹, M Stanton¹, C Murphy¹, F McCarthy¹, G Reid², C Urbaniak², W Byrne², M Tangney¹, Cork Cancer Research Centre, University College Cork, Cork Ireland</td>
</tr>
<tr>
<td></td>
<td>¹Lawson Health Research Institute, Lawson Health Research Institute, London Ontario</td>
</tr>
<tr>
<td>16.06 – 16.12</td>
<td>PERSONALISED MODELLING OF THE JNK ACTIVATION DYNAMICS CAN PREDICT NEUROBLASTOMA SURVIVAL</td>
</tr>
<tr>
<td></td>
<td>Dirk Fey¹, M Halas¹, D Dredix², SP Kennedy¹, J Hastings³, N Rauch¹, AG Munoz¹, R Pilkington¹, M Fischer⁴, F Westermann², W Kolch¹, BN Kholodenko¹, DR Croucher¹,³</td>
</tr>
<tr>
<td></td>
<td>²Systems Biology Ireland, University College Dublin, Dublin, ³Department of Neuroblastoma Genomics (B087), German Cancer Research Center (DKFZ), Heidelberg, ⁴The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, ⁵Department of Pediatric Hematology and Oncology, University Hospital Cologne, Cologne</td>
</tr>
<tr>
<td>16.12 – 16.18</td>
<td>THE ROLE OF C-MET/HGF SIGNALLING AS A CRITICAL MEDIATOR OF AN INVASIVE AND RESISTANT PHENOTYPE IN COLORECTAL CANCER</td>
</tr>
<tr>
<td></td>
<td>Conor A Bradley¹, P Dunne, D McArt, S McQuaid, M Salto-Tellez, PG Johnston, S Van Schaeybroeck, ¹CCRCB, QUB, Belfast</td>
</tr>
<tr>
<td>16.18 – 16.24</td>
<td>TOPOISOMERASE 2-α IS A NOVEL CDC7/DBF4 INTERACTING PROTEIN</td>
</tr>
<tr>
<td></td>
<td>Kevin ZL Wu¹,², G O’Brien¹,², MD Rainey¹,², C Santocanale¹,²</td>
</tr>
<tr>
<td></td>
<td>¹Centre for Chromosome Biology, NUI Galway, Galway, ²National Centre for Biomedical Engineering Science, NUI Galway, Galway</td>
</tr>
<tr>
<td>16.24 – 16.30</td>
<td>BRCA1 DEFICIENCY EXACERBATES ESTROGEN-INDUCED DNA DAMAGE AND GENOMIC INSTABILITY</td>
</tr>
<tr>
<td></td>
<td>Kyle B Matchett¹, KJ Savage¹, EM Barros¹, KM Cooper², GW Irwin¹, JJ Gorski¹, KS Orr¹, J Vohhodina¹, JN Kavanagh¹, A Barros¹, A Powell¹,², L Manti³, SS McManus³, BH Park⁴, KM Prise³, SA McIntosh³, M Salto-Tellez¹, DJ Richard³, CT Elliott³, DP Harkin¹</td>
</tr>
<tr>
<td></td>
<td>¹Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, ²Institute for Global Food Security, Queen’s University Belfast, Belfast, ³Department of Physics, University of Naples Federico II, Naples, ⁴The Sidney Kimmel Comprehensive Cancer Centre, The Johns Hopkins University School of Medicine, Baltimore, ⁵Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane</td>
</tr>
<tr>
<td>16.30 – 16.36</td>
<td>RATIONAL TARGETING OF INHIBITOR OF APOPTOSIS PROTEINS (IAPs) FOR EFFECTIVE THERAPY OF COLORECTAL CANCER</td>
</tr>
<tr>
<td></td>
<td>Nyree T Crawford, C McCann, DJJ Waugh, PG Johnston, DB Longley</td>
</tr>
<tr>
<td></td>
<td>¹Centre for Cancer Research Biology, Queen’s University, Belfast</td>
</tr>
<tr>
<td>TIME</td>
<td>TALK TITLE</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 16.36 – 16.42 | **HIGH-THROUGHPUT SCREEN IDENTIFIES A NOVEL SPECIFIC HISTONE DEACETYLASE 6 INHIBITOR THAT KILLS CHEMORESISTANT BREAST CANCER CELLS.**  
Triona Ni Chonghaile¹, B Smith², M Hemann³, JE Bradner², W Gallagher¹, A Letai³  
¹The Conway Institute of Biomolecular and Biomedical Science, University College Dublin, Dublin  
²The Department of Hematology and Oncology, Dana Farber Cancer Institute, Boston  
³The Department of Biology, Massachusetts Institute of Technology, Boston |                                                                                                                                                                       |
| 16.42 – 16.48 | **THE EDUCATION OF MSCs BY PROSTATE CANCER CELL LINE CONDITIONED MEDIA**  
Sarah Ridge¹, Ms. Shaw², Prof. Sullivan³, Prof. Giles¹, Dr. Glynn¹  
¹Prostate Cancer Institute (PCI), NUI Galway, Galway, ²Regenerative Medicine Institute (REMEDI), NUI Galway, Galway, ³Radiation Oncology, Galway University Hospital, Galway |                                                                                                                                                                       |
| 17.00 – 18.00 | **IRISH CANCER SOCIETY SCHOLAR AND FELLOW PRESENTATIONS**  
Chairs: Dr Aisling O’Connor (ICS) and Dr Jacintha O’Sullivan (TCD) |                                                                                                                                                                       |
| 17.00 – 17.15 | **TAILORING APPROACHES FOR GLOBAL EPIGENOME ANALYSIS FROM ARCHIVAL FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE SAMPLES**  
Sudipto Das¹, B Moran¹, R Klinger¹, B Fender², G Peutman³, D Smeets³, A Byrne⁴, M Ebert⁵, D Lambrechts³, WM Gallagher⁵, DP O’Connor¹⋅³, Cancer Biology & therapeutics, Conway Institute, University College Dublin, Dublin, ²Oncomark Ltd., Nova UCD, Dublin, ³Department of Translational genetics, VIB, K.U., Leuven, Belgium, ⁴Department of Physiology, Royal College of Surgeons in Ireland, Dublin, ⁵University of Heidelberg, University of Heidelberg, Manheim, Germany |                                                                                                                                                                       |
| 17.15 – 17.30 | **MicroRNA-10a IS SIGNIFICANTLY DOWN-REGULATED IN BREAST CANCER AND REGULATED AT LEAST IN PART THROUGH RETINOIC ACID**  
Sonja Khan, D Wall, C Curran, J Newell, MJ Kerin, RM Dwyer, ¹Surgery, School of Medicine, National University of Ireland, Galway, ²Clinical Research Facility and School of Mathematics, Statistics and Applied, National University of Ireland, Galway, ³Surgery, School of Medicine, National University of Ireland, Galway, ⁴Clinical Research Facility and School of Mathematics, Statistics and Applied, National University of Ireland, Galway, ⁵Surgery, School of Medicine, National University of Ireland, Galway |                                                                                                                                                                       |
| 17.30 - 17.45 | **Investigation of the role of STAT3 signalling in obesity-associated adenocarcinoma of the oesophagus**  
Katie O‘Sullivan¹, MC Cathcart¹, E O‘Regan¹, J Michaelson¹, N Gilmartin¹, A Cannon¹, G Moore¹, W Gao², U Fearon², J Lysaght¹, J O‘Sullivan¹, JV Reynolds¹  
¹Department of Surgery, Institute of Molecular Medicine, Dublin  
²Education and Research Centre, Conway Institute of Bimolecular and Biomedical Research, Elm Park, Dublin |                                                                                                                                                                       |
| 17.45 – 18.00 | **FUNCTIONAL GENOMIC SCREENING IDENTIFIES USP11 AS A NOVEL THERAPEUTIC TARGET IN BREAST CANCER**  
Lisa Dwane¹, AE O’Connor¹, L Mulrane¹, AM Dirac², K Jirstrom³, JP Crown⁴, R Bernards², WM Gallagher¹, DP O’Connor¹⋅³UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin 4, ²Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, Netherlands, ³Department of Laboratory Medicine, Malmö University Hospital, Lund University, Malmö, Sweden |                                                                                                                                                                       |
| 18.00 – 18.30 | **TEA/COFFEE & MEET THE SPONSORS** |                                                                                                                                                                       |
| 18.30 – 19.30 | **IRISH CANCER SOCIETY LECTURE – **  
*Introduced by: John McCormack*  
“GENETIC PREDISPOSITION TO PROSTATE CANCER AND ITS CLINICAL APPLICATIONS”  
Prof. Ros Eeles, The Royal Marsden & The Institute of Cancer Research, London |                                                                                                                                                                       |
<p>| 19.30 – 22.30 | <strong>FORMAL POSTER SESSION, TRADE EXHIBITION/WINE RECEPTION AND BUFFET DINNER</strong> |                                                                                                                                                                       |</p>
<table>
<thead>
<tr>
<th>TIME</th>
<th>TALK TITLE</th>
</tr>
</thead>
</table>
| 08.40 – 10.10| Proffered Paper 2 Session  
Chairs: Dr Graham Pidgeon (TCD) and Dr Niadh Buckley (QUB) |
| 08.40 – 08.55| IDENTIFICATION OF A NOVEL UBIQUITIN SPECIFIC PEPTIDASE INVOLVED IN MAINTAINING GENOMIC STABILITY  
Edel McGarry¹, David Gaboriu², Umberto Restuccia³, Michael D. Rainey¹, Angela Bachi³ and Corrado Santocanale¹.¹  
Centre for Chromosome Biology and National Centre for Biomedical Engineering Science, National University of Ireland, Galway, ²Functional Proteomics Unit, IFOM, FIRC Institute of Molecular Oncology, Milan, Italy |
| 08.55 – 09.10| INVESTIGATING THE ROLE OF POLYMORPHISMS IN mir146a AND mir196a2 IN MODIFYING BREAST CANCER RISK AND PHENOTYPE  
Robert J Mulligan¹, TP McVeigh¹, KJ Sweeney¹, JB Weidhaas¹, N Miller¹, MJ Kerin¹  
¹Discipline of Surgery, NUI Galway, Galway, ²School of Medicine, Yale University, New Haven |
| 09.10 – 09.25| ELUCIDATING THE IMMUNOTHERAPEUTIC POTENTIAL OF GAMMA DELTA T CELL SUBSETS AND MAIT CELLS  
Margaret Dunne¹, R Dunne¹, N Clarke¹, N Gilmarten¹, D O'Toole², F MacCarthy³, N Ravi³, JV Reynolds³, JN O'Sullivan¹  
¹Department of Surgery, Trinity College Dublin, Dublin, ²Department of Clinical Medicine, St James's Hospital, Dublin |
| 09.25 – 09.40| DEVELOPMENT OF AN EX-VIVO PRIMARY ACUTE MYELOID LEUKEMIA (AML) ASSAY TO PREDICT EFFICACY OF CHEMOTHERAPY  
Denis Baev¹, J Krawczyk², M O'Dwyer¹  ¹, E Szegedzi¹, ¹Aptoptosis Research Center, National University of Ireland, Galway, ²Haematology, Galway University Hospital, Galway |
| 09.40 – 09.55| THE ROLE OF ZEB1/ZEB2 AND βIII-TUBULIN IN MEDIATING DOCETAXEL-RESISTANT PROSTATE CANCER  
Karen Hanrathan¹, M Precipice¹, J Bugler¹, L Murphy¹, A O'Neill¹, RW Watson¹  
¹UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin |
| 09.55 – 10.10| Delineating An Epigenomic Roadmap of Prostate Tumorigenesis  
Presented by: Antoinette Perry  
CJ O'Rourke¹, AL Walsh¹ ¹, B Hayes¹, J Hansen⁴, S O'Meachair⁵, D Golden⁶, R Anney¹, S Madden⁷, C Morrissey⁸, R Vessella⁸, M Emmert-Buck⁴, SP Finn⁵, D Hollywood¹, T Lynch², RWG Watson⁹, Antoinette Perry¹,¹  
¹Institute of Molecular Medicine, Trinity College Dublin, Dublin 8, ²Department of Urology, St. James's Hospital, Dublin 8, ³Department of Histopathology, St. James's Hospital, Dublin 8, ⁴Pathogenetics Unit, National Cancer Institute, NIH, Bethesda, MD, USA, ⁵Dublin Centre for Clinical Research and Centre for Health Decision Science, Trinity College Dublin, Dublin 2, ⁶Trinity Centre for High Performance Computing, Trinity College Dublin, Dublin 2, ⁷National Institute for Cellular Biotechnology, Dublin City University, Dublin 9, ⁸Department of Urology, University of Washington, Seattle, USA, ⁹Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4 |
| 10.10 – 10.30| Gold Sponsor Platform – GenCell Bio  
“Powering Genomic Cancer Research using High Throughput Library Preparation for Next Generation Sequencing” |
| 10.30 – 10.55| Tea/Coffee/Posters and Meet the Sponsors |
| 10.55 – 12.25| Plenary Session 3: Growth Factor & Adhesion Signalling  
Chairs: Dr Pat Kiely (UL) and Dr Ann Hopkins (RCSI) |
| 11.05 – 11.25| “RnaI Screen Identifies New Regulators of Epithelial Cell-Cell Adhesion”  
Vania Braga, Faculty of Medicine – Imperial College, London |
| 11.25 – 11.45| “Forcing Tumor Progression and Metastasis”  
Valerie Weaver, University of California, San Francisco |
| 11.55 – 12.25| “IGF and Adhesion Signalling in Cancer Cell Stemness, EMT and Therapy Resistance”  
Rosemary O’Connor, University College Cork |
<p>| 12.25 – 12.45| Gold Sponsor Platform – Kile Green, NanoString Technologies |
| 12.45 – 14.00| Lunch |</p>
<table>
<thead>
<tr>
<th>TIME</th>
<th>TALK TITLE</th>
</tr>
</thead>
</table>
| 14.00 – 15.30 | Plenary Session 4: Longitudinal Monitoring of Acquired Resistance to Therapy  
Chairs: Darran O’Connor, UCD and Prof. Afshin Samali, NUI, Galway                                      |
| 14.00 – 14.30 | “Therapy Resistance in Human Prostate Cancer”  
Norman Maitland, University of York                                                                 |
| 14.30 – 15.00 | “Non-Invasive Cancer Genomics”  
Dr Dana Tsui, University of Cambridge                                                                 |
| 15.00 – 15.20 | IACR AGM                                                                 |
| 15.20 – 15.50 | TEA/COFFEE/POSTERS & MEET THE SPONSORS                                    |
| 15.50 – 15.40 | Plenary Session 5: Lessons from Research Centres: Translating Academic Research into  
Innovative Tools  
Chairs: Prof. William Watson, UCD and Dr Tara Dalton, UL                                      |
| 15.50 – 16.20 | “CRC-Associated Microbiota Profiles Are Linked With Distinct Mucosal Gene Expression Profiles”  
Burkhardt Flemer, PhD, Alimentary Pharmabiotic Centre & Dept., Microbiology, University College Cork |
| 16.20 – 16.50 | Professor Brian Caulfield (INSIGHT)  
Lead Investigator ARCH Centre, Dean of Physiotherapy, University College Dublin |
| 16.50 – 17.20 | BREAST-PREDICT, the Irish Cancer Society’s First Collaborative Cancer Research Centre  
William Gallagher (BREAST-PREDICT)                                                      |
| 17.20 – 18.20 | EACR Young Scientist Awards  
Chairs: Dr Ann Hopkins and Dr Jacintha O’Sullivan |
| 17.20 – 17.50 | RATIONAL DESIGN AND VALIDATION OF A TIP60 HISTONE ACETYLTRANSFERASE INHIBITOR FOR THE  
TREATMENT OF BREAST CANCER SUBTYPES  
Presented by: James Brown |
|              | C Gao, E Bourke, MC Casey, A McGuire, A Shalaby, M Webber, C Curran,  
MA Famme, T Koolmeister, M Kerin, T Helleday, LA Eriksson, NF Lowndes,  
James Brown  
1School of Chemistry, National University of Ireland Galway, Galway,  
2Department of Chemistry and Molecular Biology, University of Gothenburg, Gothenburg, Sweden,  
3Discipline of Pathology, National University of Ireland Galway, Galway,  
4Division of Translational Medicine and Chemical Biology, Department of Medi, Karolinska Institute, Stockholm, Sweden,  
5Centre for Chromosome Biology, School of Natural Sciences, National University of Ireland Galway, Galway,  
6Department of Surgery, School of Medicine, National University of Ireland Galway, Galway, Ireland |
| 17.50 – 18.20 | TARGETING COLON CANCER CELL NF-kappaB PROMOTES AN ANTI-TUMOR M1-LIKE MACROPHAGE  
PHENOTYPE AND INHIBITS PERITONEAL METASTASIS  
1Discipline of Pharmacology and Therapeutics, NUIG, Galway,  
2Regenerative Medicine Institute, NUIG, Galway |
| 18.20 – 18.30 | AWARDING OF PRIZES                                                       |
| 19.30 – 19.45 | GALA DINNER BUNRATTY CASTLE WITH ENTERTAINMENT  
TRANSPORT TO AND FROM VENUE PROVIDED – BUS DEPARTS AT 19.30!!!! |